PMGC Holdings Inc.

Expansion Program Overview

The expansion program will advance the four AI-discovered compounds through a three-phase development process designed to confirm ANT1 induction in differentiated human myotubes, further characterize their mitochondrial activity and functional effects, and progressively narrow the candidates based on the resulting data. The program is expected to take approximately 6 months and will culminate in the nomination of a lead compound and designated backup for further development.

The three phases are structured sequentially: Expansion Phase I establishes a qualified assay and standard operating procedure; Expansion Phase II confirms ANT1 induction in a more mature muscle model and produced ranked, go/no-go data for each compound; and Expansion Phase III profiles the lead candidates against Yuva Biosciences’ Mitochondrial Biogenesis Panel, quantifies cellular ATP output, and delivers an integrated mechanism-of-action hypothesis alongside the lead nomination. The result is a de-risked, nominated compound positioned for IND-enabling development in Cardiac Diseases and Obesity.